For the first time, hybrid molecules were synthesized on the basis of lithocholic and (5Z,9Z)-1,14-tetradeca-5,9-dienedicarboxylic acids, obtained in two stages using the homo-cyclomagnesiation reaction of 2-(hepta-5,6-diene-1-yloxy)tetrahydro-2H-pyran at the key stage. The resulting hybrid molecules containing 5Z,9Z-dienoic acids are of interest as novel synthetic biologically active precursors to create modern drugs for the treatment of human oncological diseases. The synthesized hybrid molecules were found to exhibit extremely high in vitro inhibitory activity against human topoisomerase I, which is 2-4 times higher than that of camptothecin, a known topoisomerase I inhibitor. Using flow cytometry and fluorescence microscopy, it was first shown that these new molecules are efficient apoptosis inducers in HeLa, U937, Jurkat, K562, and Hek293 cell cultures. In addition, the results of investigations into the effect of the synthesized acids on mitochondria and studies of possible DNA damage in Jurkat tumor cells are also presented.
For the first time, hybrid molecules were synthesized on the basis of lithocholic and n class="Chemical">(5Z,9Z)-1,14-tetradeca-5,9-dienedicarboxylic acids, obtained in two stages using the homo-cyclomagnesiation reaction of 2-(hepta-5,6-diene-1-yloxy)tetrahydro-2H-pyran at the key stage. The resulting hybrid molecules containing 5Z,9Z-dienoic acids are of interest as novel synthetic biologically active precursors to create modern drugs for the treatment of human oncological diseases. The synthesized hybrid molecules were found to exhibit extremely high in vitro inhibitory activity against human topoisomerase I, which is 2-4 times higher than that of camptothecin, a known topoisomerase I inhibitor. Using flow cytometry and fluorescence microscopy, it was first shown that these new molecules are efficient apoptosis inducers in HeLa, U937, Jurkat, K562, and Hek293 cell cultures. In addition, the results of investigations into the effect of the synthesized acids on mitochondria and studies of possible DNA damage in Jurkattumor cells are also presented.
Authors: Vladimir A D'yakonov; Lilya U Dzhemileva; Regina A Tuktarova; Svetlana R Ishmukhametova; Milyausha M Yunusbaeva; Ilfir R Ramazanova; Usein M Dzhemilev Journal: Anticancer Agents Med Chem Date: 2017 Impact factor: 2.505
Authors: Jie Cheng; Zhong-Ze Fang; Jung-Hwan Kim; Kristopher W Krausz; Naoki Tanaka; John Y L Chiang; Frank J Gonzalez Journal: J Lipid Res Date: 2013-12-16 Impact factor: 5.922
Authors: Konstantin G Lyamzaev; Natalia V Sumbatyan; Alexey M Nesterenko; Ekaterina G Kholina; Natalia Voskoboynikova; Heinz-Jürgen Steinhoff; Armen Y Mulkidjanian; Boris V Chernyak Journal: Oxid Med Cell Longev Date: 2019-11-13 Impact factor: 6.543
Authors: Ahmad Alshehri; Afza Ahmad; Rohit Kumar Tiwari; Irfan Ahmad; Ali G Alkhathami; Mohammad Y Alshahrani; Mohammed A Asiri; Tahani M Almeleebia; Mohd Saeed; Dharmendra Kumar Yadav; Irfan Ahmad Ansari Journal: Front Pharmacol Date: 2022-07-19 Impact factor: 5.988